Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin.
The accumulation of aggregates of amyloidogenic peptides is associated with numerous human diseases. One well studied example is the association between deposition of amyloid beta (Abeta) and Alzheimer's disease. Insulin degrading enzyme and neprilysin are involved in the clearance of Abeta, and presequence peptidase is suggested to play a role in the degradation of mitochondrial Abeta. Recent structural analyses reveal that these three peptidases contain a catalytic chamber (crypt) that selectively encapsulates and cleaves amyloidogenic peptides, hence the name cryptidase. The substrate selectivity of these cryptidases is determined by the size and charge distribution of their crypt as well as the conformational flexibility of substrates. The interaction of Abeta with the catalytic core of these cryptidases is controlled by conformational changes that make the catalytic chambers accessible for Abeta binding. These new structural and biochemical insights into cryptidases provide potential therapeutic strategies for the control of Abeta clearance.
Malito
E
E
Ben-May Department for Cancer Research, The University of Chicago, 929 East 57th Street, Chicago, IL 60637, United States.
Hulse
R E
RE
Tang
W-J
WJ
D000544:Alzheimer Disease / Q000628:therapy; D000595:Amino Acid Sequence; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D006801:Humans; D007339:Insulysin / Q000737:chemistry / Q000378:metabolism*; D008969:Molecular Sequence Data; D015260:Neprilysin / Q000737:chemistry / Q000378:metabolism*; D011499:Protein Processing, Post-Translational; D013379:Substrate Specificity
D016229:Amyloid beta-Peptides; D015260:Neprilysin; D007339:Insulysin